Published in Radiology on August 01, 2006
Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol (2015) 2.15
Techniques of interventional tumor therapy. Dtsch Arztebl Int (2008) 1.45
Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol (2007) 1.39
Radiofrequency ablation of lung tumors: imaging features of the postablation zone. Radiographics (2012) 1.04
Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances. Br J Radiol (2014) 1.00
Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol (2009) 0.96
Thermal ablation of lung tumors. Surg Oncol Clin N Am (2011) 0.95
Radiofrequency Ablation for Colon and Rectal Carcinoma Liver Metastases: What's Missing? Gastrointest Cancer Res (2007) 0.94
CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases. World J Surg Oncol (2012) 0.90
Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? Interact Cardiovasc Thorac Surg (2012) 0.89
Endovascular coils as lung tumour markers in real-time tumour tracking stereotactic radiotherapy: preliminary results. Eur Radiol (2008) 0.87
Comparison of therapeutic results from radiofrequency ablation and stereotactic body radiotherapy in solitary lung tumors measuring 5 cm or smaller. Int J Clin Oncol (2014) 0.86
Radiofrequency ablation of lung tumours. Insights Imaging (2011) 0.86
Hepato-pericardial fistula following radiofrequency ablation (RFA) for liver metastasis: a case report and review of the literature. Langenbecks Arch Surg (2008) 0.84
Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer. World J Gastroenterol (2014) 0.83
Lung cancer ablation: technologies and techniques. Semin Intervent Radiol (2013) 0.82
Lung cancer ablation: what is the evidence? Semin Intervent Radiol (2013) 0.81
From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel. Transl Lung Cancer Res (2016) 0.79
Imaging Features following Thermal Ablation of Lung Malignancies. Semin Intervent Radiol (2013) 0.79
Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer. AJR Am J Roentgenol (2013) 0.78
Radiofrequency ablation of pulmonary tumours: current status. Cancer Imaging (2008) 0.78
Lung radiofrequency ablation: potential as a therapy to oligometastasis and oligorecurrence. Pulm Med (2012) 0.78
Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study. Onco Targets Ther (2016) 0.77
CT-guided radiofrequency ablation for lung cancer. Int J Clin Oncol (2007) 0.77
Imaging follow-up of RF ablation of lung tumours. Cancer Imaging (2011) 0.77
Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know. Indian J Radiol Imaging (2016) 0.76
Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study. Eur J Nucl Med Mol Imaging (2013) 0.76
Current status of thermal ablation treatments for lung malignancies. Semin Intervent Radiol (2010) 0.75
Novel teatment options in early-stage non-small-cell lung cancer. EJC Suppl (2013) 0.75
Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation. Radiology (2016) 0.75
Alternative to surgery in early stage NSCLC-interventional radiologic approaches. Transl Lung Cancer Res (2013) 0.75
CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours. Eur Radiol (2016) 0.75
Diagnostic yield of a biopsy performed immediately after lung radiofrequency ablation. Eur Radiol (2016) 0.75
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol (2006) 7.05
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol (2011) 4.77
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis (2004) 3.63
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res (2005) 3.44
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol (2012) 3.06
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol (2012) 2.92
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol (2012) 2.62
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol (2011) 2.26
Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol (2009) 2.26
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol (2012) 2.26
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. Clin Breast Cancer (2010) 2.12
Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol (2003) 2.09
A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Cardiovasc Intervent Radiol (2013) 2.09
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol (2004) 2.05
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]. Gastroenterol Clin Biol (2002) 2.04
Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol (2005) 1.96
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res (2003) 1.92
Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol (2004) 1.81
Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol (2006) 1.76
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol (2010) 1.74
Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. Fertil Steril (2008) 1.72
Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol (2004) 1.72
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial. J Clin Oncol (2010) 1.64
Pulmonary radiofrequency ablation in patients with a single lung: feasibility, efficacy, and tolerance. Radiology (2011) 1.57
Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg (2015) 1.56
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Laparoscopic radical prostatectomy in renal transplant recipients. Urology (2009) 1.52
Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery (2005) 1.51
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol (2002) 1.51
Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology (2010) 1.51
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer (2007) 1.51
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50
Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. Gastroenterol Clin Biol (2007) 1.48
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer (2011) 1.45
Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology (2009) 1.45
Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology (2002) 1.44
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun (2004) 1.43
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. Arch Esp Urol (2010) 1.41
Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology (2004) 1.38
Design and synthesis of novel stiripentol analogues as potential anticonvulsants. Eur J Med Chem (2011) 1.35
BIRADS classification in mammography. Eur J Radiol (2006) 1.35
Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology (2006) 1.34
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol (2009) 1.34
Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg (2008) 1.32
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer (2012) 1.32
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 1.30
Three-dimensional spatial and temporal temperature control with MR thermometry-guided focused ultrasound (MRgHIFU). Magn Reson Med (2009) 1.28
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol (2002) 1.27
Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology (2005) 1.26